<p>Aardvark Therapeutics, Inc.是一家医疗保健行业公司，华尔街分析师于 5 月 15 日重新评估了该公司。来自美国银行证券的分析师 Tazeen Ahmad 将该股票的评级下调至卖出，并给出了 4.00 美元的目标价。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Tazeen Ahmad 之所以给予卖出评级，是由于 FDA 对 Aardvark Therapeutics 的主要项目 ARD-101 的临床暂停所带来的多种因素的综合影响，以及由此产生的开发时间表的不确定性。由于在健康志愿者中观察到高剂量的心脏问题，该公司已暂停试验，尽管管理层与 FDA 保持积极对话，并计划在普拉德 - 威利综合症的 3 期 HERO 和扩展数据中解除盲法，但尚未传达明确的时间表。</p>
<p>Ahmad 还认为，由于监管环境的变化和来自 Soleno 的 Vykat XR 及 Rhythm 的 setmelanotide 等产品的竞争加剧，AARD 未来的市场机会面临额外风险。反映这些担忧，她降低了成功的概率，推迟了 PWS 项目的假定启动，取消了之前分配给其他适应症和终端增长的价值，并提高了折现率，这些因素共同导致她将目标价从 18 美元下调至 4 美元，支持卖出立场。</p>
<p>在 5 月 15 日发布的另一份报告中，摩根士丹利也将该股票评级下调至卖出，目标价为 3.00 美元。</p>

AARD

<p>Aardvark Therapeutics, Inc. 被美国银行分析师 Tazeen Ahmad 下调至卖出评级，目标价从 18 美元下调至 4 美元。此次评级下调是由于 FDA 对其主要项目 ARD-101 因心脏问题实施临床暂停，以及来自其他产品的竞争加剧。摩根士丹利也将该股票下调至卖出，目标价为 3.00 美元</p>

<p>Aardvark Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst on May 15. Analyst Tazeen Ahmad from Bank of America Securities downgraded the rating on the stock to a Sell and gave it a $4.00 price target.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc.是一家医疗保健行业公司，华尔街分析师于 5 月 15 日重新评估了该公司。来自美国银行证券的分析师 Tazeen Ahmad 将该股票的评级下调至卖出，并给出了 4.00 美元的目标价。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Tazeen Ahmad has given his Sell rating due to a combination of factors centered on the FDA’s clinical hold of Aardvark Therapeutics’ lead program, ARD-101, and the resulting uncertainty around development timelines. The company has halted trials after cardiac issues were observed at higher doses in healthy volunteers, and although management is in active dialogue with the FDA and plans to unblind phase 3 HERO and extension data in Prader-Willi syndrome, no firm schedule has been communicated.</p>
<div class="lb-trans"><p>Tazeen Ahmad 之所以给予卖出评级，是由于 FDA 对 Aardvark Therapeutics 的主要项目 ARD-101 的临床暂停所带来的多种因素的综合影响，以及由此产生的开发时间表的不确定性。由于在健康志愿者中观察到高剂量的心脏问题，该公司已暂停试验，尽管管理层与 FDA 保持积极对话，并计划在普拉德 - 威利综合症的 3 期 HERO 和扩展数据中解除盲法，但尚未传达明确的时间表。</p>
</div><p>Ahmad also sees added risk from a changing regulatory environment and intensifying competition from products like Soleno’s Vykat XR and Rhythm’s setmelanotide, which could erode AARD’s future market opportunity. Reflecting these concerns, she lowers the probability of success and delays the assumed launch for the PWS program, removes value previously assigned to other indications and terminal growth, and raises discount rates, which collectively reduce her price objective from $18 to $4, supporting a Sell stance.</p>
<div class="lb-trans"><p>Ahmad 还认为，由于监管环境的变化和来自 Soleno 的 Vykat XR 及 Rhythm 的 setmelanotide 等产品的竞争加剧，AARD 未来的市场机会面临额外风险。反映这些担忧，她降低了成功的概率，推迟了 PWS 项目的假定启动，取消了之前分配给其他适应症和终端增长的价值，并提高了折现率，这些因素共同导致她将目标价从 18 美元下调至 4 美元，支持卖出立场。</p>
</div><p>In another report released on May 15, Morgan Stanley also downgraded the stock to a Sell with a $3.00 price target.</p>
<div class="lb-trans"><p>在 5 月 15 日发布的另一份报告中，摩根士丹利也将该股票评级下调至卖出，目标价为 3.00 美元。</p>
</div>

FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4

Tip Ranks

Aardvark Therapeutics

美国银行

Soleno治疗

Rhythm Pharma

摩根士丹利

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

由于 FDA 临床暂停和竞争压力，Aardvark Therapeutics 的评级被下调，目标价格从 18 美元大幅削减至 4 美元